Literature DB >> 18821680

Marked differences in fine specificity and isotype usage of the anti-citrullinated protein antibody in health and disease.

Andreea Ioan-Facsinay1, Annemiek Willemze, David B Robinson, Christine A Peschken, Janet Markland, Diane van der Woude, Brenda Elias, Henri A Ménard, Marianna Newkirk, Marvin J Fritzler, René E M Toes, Tom W J Huizinga, Hani S El-Gabalawy.   

Abstract

OBJECTIVE: Anti-citrullinated protein antibodies (ACPAs) display high association with rheumatoid arthritis (RA) and are implicated in its pathogenesis. The presence of ACPAs is known to precede the onset of RA. In order to identify the features that could confer its pathogenicity, we extensively characterized this antibody response in a unique North American native population of patients with RA and their unaffected relatives.
METHODS: The levels of IgA, IgM, and IgG ACPAs, as well as IgM and IgA rheumatoid factor (RF), were measured in serum samples obtained from 81 patients with RA and 195 of their unaffected relatives. The isotype distribution, the fine specificity of the ACPA response, and its association with RF were compared in health and disease.
RESULTS: ACPA positivity was observed in 19% of the healthy relatives and approximately 91% of the patients with RA. ACPA isotype usage was strikingly lower in unaffected relatives than in patients with RA (1-2 versus 5-6 isotypes). Fine specificity studies showed that reactivity to citrullinated fibrinogen and vimentin was present in sera from patients with RA, while it was virtually absent in their unaffected relatives. Finally, the ACPA and RF responses were associated in patients with RA but were discordant in their healthy relatives. Extended analyses revealed that the presence of ACPAs was associated with RA irrespective of RF status, while the association of RF with disease relied on its interaction with ACPAs.
CONCLUSION: The fine specificity and isotype usage of the ACPA response are qualitatively different in health and disease. Epitope spreading and expansion of the isotype repertoire might be necessary for development of RA, and this could be facilitated by the presence of RF antibodies.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18821680     DOI: 10.1002/art.23763

Source DB:  PubMed          Journal:  Arthritis Rheum        ISSN: 0004-3591


  55 in total

1.  The problems and promises of research into human immunology and autoimmune disease.

Authors:  Bart O Roep; Jane Buckner; Stephen Sawcer; Rene Toes; Frauke Zipp
Journal:  Nat Med       Date:  2012-01-06       Impact factor: 53.440

Review 2.  The pathogenic potential of autoreactive antibodies in rheumatoid arthritis.

Authors:  Marieke Bax; Tom W J Huizinga; René E M Toes
Journal:  Semin Immunopathol       Date:  2014-04-25       Impact factor: 9.623

Review 3.  Autoantibodies in systemic autoimmune diseases: specificity and pathogenicity.

Authors:  Jolien Suurmond; Betty Diamond
Journal:  J Clin Invest       Date:  2015-05-04       Impact factor: 14.808

4.  Timing of Elevations of Autoantibody Isotypes Prior to Diagnosis of Rheumatoid Arthritis.

Authors:  Lindsay B Kelmenson; Brandie D Wagner; Bryan K McNair; Ashley Frazer-Abel; M Kristen Demoruelle; Dylan T Bergstedt; Marie L Feser; Laura K Moss; Mark C Parish; Elizabeth A Mewshaw; Ted R Mikuls; Jess D Edison; V Michael Holers; Kevin D Deane
Journal:  Arthritis Rheumatol       Date:  2019-12-26       Impact factor: 10.995

5.  Recognition of new citrulline-containing peptide epitopes by autoantibodies produced in vivo and in vitro by B cells of rheumatoid arthritis patients.

Authors:  Eszter Szarka; Fruzsina Babos; Anna Magyar; Krisztina Huber; Zoltán Szittner; Krisztián Papp; József Prechl; Judit Pozsgay; Zsuzsa Neer; Monika Ádori; György Nagy; Bernadette Rojkovich; Tamás Gáti; Judit Kelemen; Zsuzsanna Baka; Márta Brózik; Borbála Pazár; Gyula Poór; Ferenc Hudecz; Gabriella Sármay
Journal:  Immunology       Date:  2014-02       Impact factor: 7.397

6.  Anti-cyclic citrullinated peptide antibodies in scleroderma patients.

Authors:  M Polimeni; D Feniman; T S Skare; Renato M Nisihara
Journal:  Clin Rheumatol       Date:  2012-01-04       Impact factor: 2.980

7.  Label-free detection of immune complexes with myeloid cells.

Authors:  Z Szittner; A E H Bentlage; P Rovero; P Migliorini; V Lóránd; J Prechl; G Vidarsson
Journal:  Clin Exp Immunol       Date:  2016-05-12       Impact factor: 4.330

8.  Fine specificity of anti-citrullinated peptide antibodies discloses a heterogeneous antibody population in rheumatoid arthritis.

Authors:  J D Goules; A V Goules; A G Tzioufas
Journal:  Clin Exp Immunol       Date:  2013-10       Impact factor: 4.330

9.  Cross-reactivity of a human IgG₁ anticitrullinated fibrinogen monoclonal antibody to a citrullinated profilaggrin peptide.

Authors:  Nicole Hartwig Trier; Maria Louise Leth; Paul Robert Hansen; Gunnar Houen
Journal:  Protein Sci       Date:  2012-11-09       Impact factor: 6.725

Review 10.  Clinical approaches to early inflammatory arthritis.

Authors:  Dirkjan van Schaardenburg; Ben A C Dijkmans
Journal:  Nat Rev Rheumatol       Date:  2009-09-29       Impact factor: 20.543

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.